



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



ELSEVIER

Contents lists available at ScienceDirect

International Journal of Infectious Diseases

journal homepage: www.elsevier.com/locate/ijid

Short Communication

Clinical Characteristics of Patients with Coronavirus Disease (COVID-19): Preliminary Baseline Report of Japan COVID-19 Task Force, a Nationwide Consortium to Investigate Host Genetics of COVID-19[☆]



Hiromu Tanaka¹, Ho Lee¹, Atsuhō Morita¹, Ho Namkoong^{2,#}, Shotaro Chubachi¹, Hiroki Kabata¹, Hirofumi Kamata¹, Makoto Ishii¹, Naoki Hasegawa², Norihiro Harada³, Tetsuya Ueda⁴, Soichiro Ueda⁵, Takashi Ishiguro⁶, Ken Arimura⁷, Fukuki Saito⁸, Takashi Yoshiyama⁹, Yasushi Nakano¹⁰, Yoshikazu Mutoh¹¹, Yusuke Suzuki¹², Koji Murakami¹³, Yukinori Okada^{14,15,16,17}, Ryuji Koike¹⁸, Yuko Kitagawa¹⁹, Katsushi Tokunaga²⁰, Akinori Kimura²¹, Seiya Imoto²², Satoru Miyano²³, Seishi Ogawa^{24,25,26}, Takanori Kanai²⁷, Koichi Fukunaga¹, The Japan COVID-19 Task Force

¹ Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan² Department of Infectious Diseases, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan³ Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan⁴ Department of Respiratory Medicine, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan⁵ JCHO (Japan Community Health Care Organization) Saitama Medical Center, Internal Medicine, Saitama, Japan⁶ Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Kumagaya, Japan⁷ Department of Respiratory Medicine, Tokyo Women's Medical University, Tokyo, Japan⁸ Department of Emergency and Critical Care Medicine, Kansai Medical University General Medical Center, Moriguchi, Japan⁹ Fukujiji Hospital, Kiyose, Japan¹⁰ Kawasaki Municipal Ida Hospital, Department of Internal Medicine, Kawasaki, Japan¹¹ Department of Infectious Diseases, Tosei General Hospital, Seto, Japan¹² Department of Respiratory Medicine, Kitasato University, Kitasato Institute Hospital, Tokyo, Japan¹³ Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan¹⁴ Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan¹⁵ Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita, Japan¹⁶ The Center for Infectious Disease Education and Research (CiDER), Osaka University, Suita, Japan¹⁷ Laboratory of Statistical Immunology, Immunology Frontier Research Center (WPI-IFReC), Osaka University, Suita, Japan¹⁸ Medical Innovation Promotion Center, Tokyo Medical and Dental University, Tokyo, Japan¹⁹ Department of Surgery, Keio University School of Medicine, Tokyo, Japan²⁰ Genome Medical Science Project (Toyama), National Center for Global Health and Medicine, Tokyo, Japan²¹ Institute of Research, Tokyo Medical and Dental University, Tokyo, Japan²² Division of Health Medical Intelligence, Human Genome Center, the Institute of Medical Science, the University of Tokyo, Tokyo, Japan²³ M&D Data Science Center, Tokyo Medical and Dental University, Tokyo, Japan²⁴ Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan²⁵ Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan²⁶ Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden²⁷ Division of Gastroenterology and Hepatology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan

ARTICLE INFO

Article history:

Received 18 July 2021

Revised 24 September 2021

Accepted 24 September 2021

ABSTRACT

Background and design: The coronavirus disease (COVID-19) pandemic is having a devastating effect worldwide. Host genome differences between populations may influence the severity of COVID-19.

The Japan COVID-19 Task Force is conducting host genome analysis of hospitalized patients with COVID-19 from more than 70 institutions nationwide in Japan. This report describes the clinical characteristics of patients enrolled to date.

[☆] Details are given in the "author information" section.

[#] Corresponding author: Ho Namkoong, MD, PhD. Department of Infectious Diseases, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo 160-8582, Japan.

Keywords:

COVID-19

Clinical character

Pneumonia

Host genetics

Japan

Results: The median (interquartile range) age of the 1674 patients included in the analysis was 59 (45–71) years, and more than half of the patients (66.2%) were male. Less than half of the patients (41.2%) had severe disease. The case fatality rate was 3.2%.

Conclusions: Since this is a hospital-based study, the number of severe cases was relatively high, but the case fatality rate was relatively low, when compared to that of other countries. In the future, we will continue to enroll patients and conduct genome analyses of patients with COVID-19.

© 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

The coronavirus disease (COVID-19) pandemic has had a devastating effect worldwide, including in Japan (see <https://www.mhlw.go.jp/stf/covid-19/kokunainohasseijoukyou.html>) (Ministry of Health, Labour and Welfare 2021). Host genome differences between populations may influence disease severity. This may explain why Asians, including Japanese, may have a lower risk of death (Price-Haywood, 2020; Zeberg and Pääbo, 2020). The Japan COVID-19 Task Force was established in early 2020 as a nationwide multicenter consortium. We collected and analyzed clinical specimens from patients in more than 70 institutions nationwide since February 2020 and reported the results of a genome-wide association study (Namkoong H et al., 2021).

This cross-sectional study aimed to determine the clinical characteristics of Japanese patients with COVID-19. The study facilities provide coverage for the most populous prefectural capital cities in Japan. We included 1645 (98.3%) patients with reverse transcription polymerase chain reaction (RT-PCR)-confirmed COVID-19, 10 (0.6%) patients with rapid antigen test-confirmed COVID-19, and 19 (1.1%) patients who were considered as highly suspicious for COVID-19 by the physician. We collected information on patient demographics, laboratory test data, radiographic imaging, treatment, comorbidities, and outcomes for 1674 cases to construct a database for the Japan COVID-19 Task Force. The cases were not limited to inpatients; however, 1668 (99.6%) patients were hospitalized patients. All the patients in this study provided appropriate informed consent, which was approved by the ethics committee of the affiliated institutes. Symptoms and signs included not only those reported on referral or admission but also those observed during hospitalization. Laboratory and radiographic data were collected within 48 hours of the initial visit or admission. Disease outcome during hospitalization was assessed for fatality rate. We obtained information regarding any support using oxygen devices, invasive mechanical ventilation (IMV), and extracorporeal membrane oxygenation (ECMO) during the clinical course to determine the disease severity. In this report, disease severity was defined as follows: most severe, patients requiring support using high-flow oxygen devices, IMV, ECMO, or death; severe, patients requiring support using low-flow oxygen devices; mild, symptomatic patients not requiring oxygen support; asymptomatic, asymptomatic patients not requiring oxygen support (World Health Organization, 2020).

The patients' clinical characteristics are shown in Table 1. Their median (interquartile range) age was 59 (45–71) years, 66.2% were male, and most patients were Japanese. Comorbidities included hypertension (34.6%), diabetes mellitus (22.9%), coronary artery disease (9.9%), and chronic kidney disease (7.0%). Moreover, 231 cases were categorized as most severe (13.8%), 459 cases as severe (27.4%), 933 cases as mild (55.7%), and 51 cases as asymptomatic (3.0%). The most common symptom was fever ($\geq 37.5^\circ\text{C}$), which was observed in 79.3% of patients. Cough, sputum, shortness of breath, dysgeusia, and dysosmia were observed in 58.2%, 24.7%, 30.7%, 18.7%, and 17.0% of patients, respectively. Most patients were enrolled in April 2020 (first wave), August 2020 (second wave),

and December 2020 (third wave) (Figure 1). Supplementary Table 1 shows the patients' characteristics in each epidemic. There was a high prevalence of elderly males among patients in the third epidemic. They also had a higher prevalence of comorbidities such as hypertension, diabetes, and chronic kidney disease, and a low prevalence of dysgeusia and dysosmia.

Laboratory findings showed an elevated inflammatory response, with median ferritin and C-reactive protein levels of 376 ng/mL and 2.69 mg/dL, respectively. Regarding radiographic findings, 81.3% of patients had ground glass opacity (GGO), and 39.8% had consolidation on chest computed tomography. The bilateral spread of GGOs was generally present during the acute phase of COVID-19.

A total of 19.0% of patients were admitted to the intensive care unit, 11.1% were intubated, and 2.3% required ECMO. The fatality rate was 3.2%. Complications included bacterial infection and thrombosis in 11.9% and 3.6% of patients, respectively. The most commonly used antivirals were favipiravir and remdesivir, which were used in 35.9% and 18.9% of patients, respectively. Systemic corticosteroids were used in 40.9% of patients, especially in 58.9% of patients in the third epidemic.

Clinical characteristics of patients in this study were similar to those of other previously reported large-sample studies in Asian populations (Guan, 2020; Matsunaga N et al., 2020). The proportion of male patients was higher in this study than in other studies, which may be due to the relatively high disease severity in males (Chen N et al., 2020). The proportion of patients with comorbidities such as hypertension, diabetes, and chronic kidney disease was higher than that reported in another registry in Japan (Matsunaga N et al., 2020). We believe that this finding is due to a large number of patients registered in the third epidemic, unlike




Figure 1. Coronavirus disease (COVID-19) epidemic trend in Japan, from February 2020 to February 2021. The epidemic curve shows the three epidemic waves during 1 year in Japan. ■ Red bar shows the first wave including 89 patients in this study; from April 1 to 28, 2020. ■ Blue bar shows the second wave including 468 patients in this study; from July 1 to September 1, 2020. ■ Green bar shows the third wave including 564 patients in this study; from November 18, 2020 to February 9, 2021. ■ Black bar shows the number of new patients during the period not included in the three epidemic waves. We created this figure using GraphPad Prism 9 (GraphPad Software, San Diego, California).

Table 1
Characteristics of 1674 patients with COVID-19 in Japan

| Parameters | Number of patients with data | Subcategories | n (%) or median and IQR |
|---------------------------------------|------------------------------|-----------------------------------|-------------------------|
| Severity classification | 1674 | | |
| | | Asymptomatic | 51 (3.0) |
| | | Mild | 933 (55.7) |
| | | Severe | 459 (27.4) |
| | | Most severe | 231 (13.8) |
| Death at discharge | 1633 | | 52 (3.2) |
| Age, years | 1674 | | 59 (45–71) |
| Sex | 1674 | | |
| | | Male | 1109 (66.2) |
| | | Female | 565 (33.8) |
| Population | 1674 | | |
| | | Japanese | 1629 (97.3) |
| | | Others | 45 (2.7) |
| BMI, kg/m ² | 1525 | | 23.9 (21.6–26.9) |
| Smoking history | 1547 | | |
| | | Never | 840 (54.3) |
| | | Previously or currently | 707 (45.7) |
| Chronic medical conditions | | | |
| Hypertension | 1643 | | 569 (34.6) |
| Diabetes mellitus | 1654 | | 379 (22.9) |
| Coronary artery disease | 1657 | | 164 (9.9) |
| Malignancy | 1640 | | 97 (5.9) |
| Autoimmune disease | 1653 | | 61 (3.7) |
| COPD | 1651 | | 67 (4.1) |
| Chronic liver disease | 1592 | | 53 (3.3) |
| Chronic kidney disease | 1579 | | 110 (7.0) |
| Symptoms at referral | | | |
| Fever ($\geq 37.5^{\circ}\text{C}$) | 1653 | | 1311 (79.3) |
| Cough | 1648 | | 959 (58.2) |
| Sputum | 1642 | | 405 (24.7) |
| Sore throat | 1628 | | 387 (23.8) |
| Rhinorrhoea | 1634 | | 232 (14.2) |
| Dysgeusia | 1635 | | 305 (18.7) |
| Dysosmia | 1634 | | 278 (17.0) |
| Shortness of breath | 1616 | | 496 (30.7) |
| Fatigue | 1642 | | 811 (49.4) |
| Laboratory tests | | | |
| WBC [cells/ μL] | 1613 | | 5200 (4100–6700) |
| LDH [IU/L] | 1634 | | 237 (190–314) |
| Ferritin [ng/mL] | 1269 | | 376 (171–711) |
| KL-6 [U/mL] | 1213 | | 234 (178–350) |
| PCT [ng/mL] | 1165 | | 0.06 (0.04–0.11) |
| CRP [mg/dL] | 1628 | | 2.69 (0.51–6.87) |
| Radiographic imaging | | | |
| Chest radiography findings | 1556 | | |
| | | Bilateral thoracic opacities | 834 (53.6) |
| | | Unilateral thoracic opacities | 180 (11.6) |
| | 1539 | Bilateral thoracic consolidation | 305 (19.8) |
| | | Unilateral thoracic consolidation | 121 (7.9) |
| Chest CT findings | 1480 | | |
| | | Bilateral GGO | 1055 (71.3) |
| | | Unilateral GGO | 148 (10.0) |
| | 1445 | Bilateral consolidation | 465 (32.2) |
| | | Unilateral consolidation | 110 (7.6) |
| Complications after referral | | | |
| Bacterial infection | 1653 | | 196 (11.9) |
| Heart failure | 1641 | | 36 (2.2) |
| Thrombosis | 1623 | | 59 (3.6) |
| COVID-19 treatment | | | |
| ICU admission | 1650 | | 314 (19.0) |
| Intubation | 1649 | | 183 (11.1) |
| ECMO | 1641 | | 37 (2.3) |
| Antiviral drugs | | | |
| | 1657 | Favipiravir | 595 (35.9) |
| | 1645 | Ritonavir | 7 (0.4) |
| | 1648 | Remdesivir | 311 (18.9) |
| Hydroxychloroquine | 1647 | | 18 (1.1) |
| Tocilizumab | 1643 | | 118 (7.2) |
| Systemic corticosteroid | 1663 | | 680 (40.9) |

Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease; CRP, C-reactive protein; CT, computed tomography; ECMO, extracorporeal membrane; GGO, ground glass opacity; ICU, intensive care unit; IQR, interquartile range; KL-6, Krebs von den Lungen-6; LDH, lactate dehydrogenase; PCT, procalcitonin; WBC, white blood cell.

the situation in the previously reported registry. Our study suggests that the number of hospitalized older male patients with more comorbidities has gradually increased in Japan during the past year. Compared with the recent meta-analyses in other countries (Macedo A et al., 2021), we believe that the lower fatality rate in this study and in the previous report (Matsunaga N et al., 2020) may be explained by reasons specific to Japan. We consider the possibility that many inpatient cases of our study would have been treated as outpatients in other countries, because in Japan, the public health centers coordinated the hospitalization of many patients, including those with mild disease. The low fatality rate may also reflect the unique genetic characteristics of the Japanese. For example, the effect of DOCK2 on disease severity of COVID-19 has been reported (Namkoong H et al., 2021). Our study had a large group of patients treated with remdesivir, especially in the third epidemic. A relatively high proportion of patients were treated with systemic corticosteroids, based on the results of the RECOVERY trial (Horby, 2021). These treatments may have resulted in a lower fatality rate in this study than that in previous reports.

With this clinical information, characterization of the host genomic factors in a representative sample of Japanese patients may provide insights into new treatment approaches.

Funding Source

This study was supported by AMED (JP20nk0101612, JP20fk0108415, JP21jk0210034, JP21km0405211, and JP21km0405217), JST CREST (JPMJCR20H2), MHLW (20CA2054), Takeda Science Foundation, the Mitsubishi Foundation, and Bioinformatics Initiative of Osaka University Graduate School of Medicine, Osaka University.

Ethics Approval

This study was approved by the ethics committee of Keio University School of Medicine (20200061) and affiliated institutes.

Author Information

Japan COVID-19 Task Force are composed of more than 70 institutions nationwide in Japan. The members who contributed to the collection and analysis of cases at each institution are shown as coauthors in the following list.

Hiromu Tanaka¹, Ho Lee¹, Atsuhiko Morita¹, Ho Namkoong², Shotaro Chubachi¹, Hiroki Kabata¹, Hirofumi Kamata¹, Makoto Ishii¹, Naoki Hasegawa², Kazuhisa Takahashi³, Norihiro Harada³, Toshio Naito⁴, Makoto Hiki^{5,6}, Yasushi Matsushita⁷, Haruhi Takagi³, Ryosuke Aoki⁸, Ai Nakamura³, Sonoko Harada^{3,9}, Hitoshi Sasano³, Katsunori Masaki¹, Shinnosuke Ikemura¹, Satoshi Okamori¹, Hideki Terai¹, Takanori Asakura¹, Junichi Sasaki¹⁰, Hiroshi Morisaki¹¹, Yoshifumi Uwamino¹², Kosaku Nanki¹³, Yohei Mikami¹³, Sho Uchida², Shunsuke Uno², Rino Ishihara¹³, Yuta Matsubara¹³, Tomoyasu Nishimura^{2,14}, Takunori Ogawa¹, Toshiro Sato¹⁵, Tetsuya Ueda¹⁶, Masanori Azuma¹⁶, Ryuichi Saito¹⁶, Toshikatsu Sado¹⁶, Yoshimune Miyazaki¹⁶, Ryuichi Sato¹⁶, Yuki Haruta¹⁶, Tadao Nagasaki¹⁶, Yoshinori Yasui¹⁷, Yoshinori Hasegawa¹⁶, Soichiro Ueda¹⁸, Ai Tada¹⁸, Masayoshi Miyawaki¹⁸, Masaomi Yamamoto¹⁸, Eriko Yoshida¹⁸, Reina Hayashi¹⁸, Tomoki Nagasaka¹⁸, Sawako Arai¹⁸, Yutarō Kaneko¹⁸, Kana Sasaki¹⁸, Takashi Ishiguro¹⁹, Taisuke Isono¹⁹, Shun Shibata¹⁹, Yuma Matsui¹⁹, Chiaki Hosoda¹⁹, Kenji Takano¹⁹, Takashi Nishida¹⁹, Yoichi Kobayashi¹⁹, Yotaro Takaku¹⁹, Noboru Takayanagi¹⁹, Etsuko Tagaya²⁰, Masatoshi Kawana²¹, Ken Arimura²⁰, Yasushi Nakamori²², Kazuhisa Yoshiya²², Fukuki Saito²², Tomoyuki Yoshihara²², Daiki Wada²², Hiromu Iwamura²², Syuji Kanayama²², Shuhei Maruyama²², Takanori Hasegawa²³,

Kunihiko Takahashi²³, Tatsuhiko Anzai²³, Satoshi Ito²³, Aki-fumi Endo²⁴, Yuji Uchimura²⁵, Yasunari Miyazaki²⁶, Takayuki Honda²⁶, Tomoya Tateishi²⁶, Shuji Tohda²⁷, Naoya Ichimura²⁷, Kazunari Sonobe²⁷, Chihiro Tani Sassa²⁷, Jun Nakajima²⁷, Masumi Ai²⁸, Takashi Yoshiyama²⁹, Ken Ohta²⁹, Hiroyuki Kokuto²⁹, Hideo Ogata²⁹, Yoshiaki Tanaka²⁹, Kenichi Arakawa²⁹, Masafumi Shimoda²⁹, Takeshi Osawa²⁹, Yasushi Nakano³⁰, Yukiko Nakajima³⁰, Ryusuke Anan³⁰, Ryusuke Arai³⁰, Yuko Kurihara³⁰, Yuko Harada³⁰, Kazumi Nishio³⁰, Yoshikazu Mutoh³¹, Tomonori Sato³², Reoto Takei³², Satoshi Hagimoto³², Yoichiro Noguchi³², Yasuhiko Yamano³², Hajime Sasano³², Sho Ota³², Yusuke Suzuki³³, Sohei Nakayama³³, Keita Masuzawa³³, Tomomi Takano³⁴, Kazuhiko Katayama³⁵, Koji Murakami³⁶, Mitsuhiro Yamada³⁶, Hisatoshi Sugiura³⁶, Hirohito Sano³⁶, Shuichiro Matsumoto³⁶, Nozomu Kimura³⁶, Yoshinao Ono³⁶, Hiroaki Baba³⁷, Rie Baba³⁸, Daisuke Arai³⁸, Takayuki Ogura³⁸, Hidenori Takahashi³⁸, Shigehiro Hagiwara³⁸, Genta Nagao³⁸, Shunichiro Konishi³⁸, Ichiro Nakachi³⁸, Hiroki Tateno³⁹, Isano Hase³⁹, Shuichi Yoshida³⁹, Shoji Suzuki³⁹, Miki Kawada⁴⁰, Hirohisa Horinouchi⁴¹, Fumitake Saito⁴², Keiko Mitamura⁴³, Masao Hagihara⁴⁴, Junichi Ochi⁴², Tomoyuki Uchida⁴⁴, Ryuya Eda^{45,46}, Yuya Shirai^{45,46}, Kyuto Sonehara^{46,47}, Tatsuhiko Naito⁴⁶, Kenichi Yamamoto⁴⁶, Shinichi Namba⁴⁶, Ken Suzuki⁴⁶, Takayuki Shiroyama⁴⁵, Yuichi Maeda⁴⁵, Takuro Nii⁴⁵, Yoshimi Noda⁴⁵, Takayuki Niitsu⁴⁵, Yuichi Adachi⁴⁵, Takatoshi Enomoto⁴⁵, Saori Amiya⁴⁵, Reina Hara⁴⁵, Toshihiro Kishikawa^{46,48,50}, Shuhei Yamada⁴⁹, Shuhei Kawabata⁴⁹, Noriyuki Kijima⁴⁹, Masatoshi Takagaki^{49,54}, Noa Sasa^{46,48}, Yuya Ueno⁴⁸, Motoyuki Suzuki⁴⁸, Norihiko Takemoto⁴⁸, Hirotaka Eguchi⁴⁸, Takahito Fukusumi⁴⁸, Takao Imai⁴⁸, Munehisa Fukushima^{48,53}, Haruhiko Kishima⁴⁹, Hidenori Inohara⁴⁸, Kazunori Tomono⁵¹, Kazuto Kato⁵², Haruhiko Hirata⁴⁵, Yoshito Takeda⁴⁵, Atsushi Kumanogoh^{45,47,54,55}, Naoki Miyazawa⁵⁶, Yasuhiro Kimura⁵⁶, Reiko Sado⁵⁶, Hideyasu Sugimoto⁵⁶, Akane Kamiya⁵⁷, Naota Kuwahara⁵⁸, Akiko Fujiwara⁵⁸, Tomohiro Matsunaga⁵⁸, Yoko Sato⁵⁸, Takenori Okada⁵⁸, Takashi Inoue⁵⁹, Toshiyuki Hirano⁵⁹, Keigo Kobayashi⁵⁹, Hatsuyo Takaoka⁵⁹, Koichi Nishi⁶⁰, Masaru Nishitsuji⁶⁰, Mayuko Tani⁶⁰, Junya Suzuki⁶⁰, Hiroki Nakatsumi⁶⁰, Hidefumi Koh⁶¹, Tadashi Manabe⁶¹, Yohei Funatsu⁶¹, Fumimaro Ito⁶¹, Takahiro Fukui⁶¹, Keisuke Shinozuka⁶¹, Sumiko Kohashi⁶¹, Masatoshi Miyazaki⁶¹, Tomohisa Shoko⁶², Mitsuaki Kojima⁶², Tomohiro Adachi⁶², Motonao Ishikawa⁶³, Kenichiro Takahashi⁶⁴, Kazuyoshi Watanabe⁶⁵, Yoshihiro Hirai⁶⁶, Hidetoshi Kawashima⁶⁶, Atsuya Narita⁶⁶, Kazuki Niwa⁶⁷, Yoshiyuki Sekikawa⁶⁷, Hisako Sageshima⁶⁸, Yoshihiko Nakamura⁶⁹, Kota Hoshino⁶⁹, Junichi Maruyama⁶⁹, Hiroyasu Ishikura⁶⁹, Tohru Takata⁷⁰, Takashi Ogura⁷¹, Hideya Kitamura⁷¹, Eri Hagiwara⁷¹, Kota Murohashi⁷¹, Hiroko Okabayashi⁷¹, Takao Mochimaru^{72,73}, Shigenari Nukaga⁷², Ryosuke Satomi⁷², Yoshitaka Oyama⁷³, Nobuaki Mori⁷⁴, Tomoya Baba⁷⁵, Yasutaka Fukui⁷⁵, Mitsuru Odate⁷⁵, Shuko Mashimo⁷⁵, Yasushi Makino⁷⁵, Kazuma Yagi⁷⁶, Mizuha Hashiguchi⁷⁶, Junko Kagyo⁷⁶, Tetsuya Shiomi⁷⁶, Kodai Kawamura⁷⁷, Kazuya Ichikado⁷⁷, Kenta Nishiyama⁷⁷, Hiroyuki Muranaka⁷⁷, Kazunori Nakamura⁷⁷, Satoshi Fuke⁷⁸, Hiroshi Saito⁷⁸, Tomoya Tsuchida⁷⁹, Shigeki Fujitani⁸⁰, Mumon Takita⁸⁰, Daiki Morikawa⁸⁰, Toru Yoshida⁸⁰, Takehiro Izumo⁸¹, Minoru Inomata⁸¹, Naoyuki Kuse⁸¹, Nobuyasu Awano⁸¹, Mari Tone⁸¹, Akihiro Ito⁸², Toshio Odani⁸³, Masaru Amishima⁸⁴, Takeshi Hattori⁸⁴, Yasuo Shichinohe⁸⁵, Takashi Kagaya⁸⁶, Toshiyuki Kita⁸⁶, Kazuhide Ohta⁸⁶, Satoru Sakagami⁸⁶, Kiyoshi Koshida⁸⁶, Morio Nakamura⁸⁶, Koutaro Yokote⁸⁷, Taka-Aki Nakada⁸⁸, Ryuzo Abe⁸⁸, Taku Oshima⁸⁸, Tadanaga Shimada⁸⁸, Kentaro Hayashi⁸⁹, Tetsuo Shimizu⁸⁹, Yutaka Kozu⁸⁹, Hisato Hiranuma⁸⁹, Yasuhiro Gon⁸⁹, Namiki Izumi⁹⁰, Kaoru Nagata⁹⁰, Ken Ueda⁹⁰, Reiko Taki⁹⁰, Satoko Hanada⁹⁰, Naozumi Hashimoto⁹¹, Keiko Wakahara⁹¹, Koji Sakamoto⁹¹, Norihito Omote⁹¹, Akira Ando⁹¹, Yu Kusaka⁹², Takehiko Ohba⁹², Susumu Isogai⁹², Aki Ogawa⁹²,

- Takuya Inoue⁹², Nobuhiro Kodama⁹³, Yasunari Kaneyama⁹³, Shunsuke Maeda⁹³, Takashige Kuraki⁹⁴, Takemasa Matsumoto⁹⁴, Masahiro Harada⁹⁵, Takeshi Takahashi⁹⁵, Hiroshi Ono⁹⁵, Toshihiro Sakurai⁹⁵, Takayuki Shibusawa⁹⁵, Yusuke Kawamura⁹⁶, Akiyoshi Nakayama⁹⁶, Hirotaka Matsuo⁹⁶, Yoshifumi Kimizuka⁹⁷, Akihiko Kawana⁹⁷, Tomoya Sano⁹⁷, Chie Watanabe⁹⁷, Ryohei Suematsu⁹⁷, Makoto Masuda⁹⁸, Aya Wakabayashi⁹⁸, Hiroki Watanabe⁹⁸, Suguru Ueda⁹⁸, Masanori Nishikawa⁹⁸, Ayumi Yoshifuji⁹⁹, Kazuto Ito⁹⁹, Saeko Takahashi¹⁰⁰, Kota Ishioka¹⁰⁰, Yusuke Chihara¹⁰¹, Mayumi Takeuchi¹⁰¹, Keisuke Onoi¹⁰¹, Jun Shinozuka¹⁰¹, Atsushi Sueyoshi¹⁰¹, Yoji Nagasaki¹⁰², Masaki Okamoto^{103,104}, Sayoko Ishihara¹⁰⁵, Masatoshi Shimo¹⁰⁵, Yoshihisa Tokunaga^{103,104}, Masafumi Watanabe¹⁰⁶, Sumito Inoue¹⁰⁶, Akira Igarashi¹⁰⁶, Masamichi Sato¹⁰⁶, Nobuyuki Hizawa¹⁰⁷, Yoshiaki Inoue¹⁰⁸, Shigeru Chiba¹⁰⁹, Kunihiro Yamagata¹¹⁰, Yuji Hiramatsu¹¹¹, Hira-yasu Kai¹¹⁰, Satoru Fukuyama¹¹², Yoshihiro Eriguchi¹¹³, Akiko Yonekawa¹¹³, Keiko Kan-o¹¹², Koichiro Matsumoto¹¹², Kensuke Kanaoka¹¹⁴, Shoichi Ihara¹¹⁴, Kiyoshi Komuta¹¹⁴, Koichiro Asano¹¹⁵, Tsuyoshi Oguma¹¹⁵, Yoko Ito¹¹⁵, Satoru Hashimoto¹¹⁶, Masaki Yamasaki¹¹⁶, Yu Kasamatsu¹¹⁷, Yuko Komase¹¹⁸, Naoya Hida¹¹⁸, Takahiro Tsuburai¹¹⁸, Baku Oyama¹¹⁸, Yuichiro Kitagawa¹¹⁹, Tet-suya Fukuta¹¹⁹, Takahito Miyake¹¹⁹, Shozo Yoshida¹¹⁹, Shinji Ogura¹¹⁹, Minoru Takada¹²⁰, Hidenori Kanda¹²⁰, Shinji Abe¹²¹, Yuta Kono¹²¹, Yuki Togashi¹²¹, Hiroyuki Takoi¹²¹, Ryota Kikuchi¹²¹, Shinichi Ogawa¹²², Tomouki Ogata¹²², Shoichiro Ishihara¹²², Arihiko Kanehiro^{123,124}, Shinji Ozaki¹²³, Yasuko Fuchimoto¹²³, Sae Wada¹²³, Nobukazu Fujimoto¹²⁴, Kei Nishiyama¹²⁵, Mariko Terashima¹²⁶, Satoru Beppu¹²⁶, Kosuke Yoshida¹²⁶, Osamu Narumoto¹²⁷, Hideaki Nagai¹²⁷, Nobuharu Ooshima¹²⁷, Mitsuru Motegi¹²⁸, Akira Umeda¹²⁹, Kazuya Miyagawa¹³⁰, Hisato Shimada¹³¹, Mayu Endo¹³², Yoshiyuki Ohira¹³³, Hironori Sagara¹³³, Akihiko Tanaka¹³³, Shin Ohta¹³³, Tomoyuki Kimura¹³³, Yoko Shibata¹³⁴, Yoshinori Tanino¹³⁴, Takefumi Nikaido¹³⁴, Hiroyuki Minemura¹³⁴, Yuki Sato¹³⁴, Yuichiro Yamada¹³⁵, Takuya Hashino¹³⁵, Masato Shinoki¹³⁵, Hajime Iwagoe¹³⁶, Hiroshi Takahashi¹³⁷, Kazuhiko Fujii¹³⁷, Hiroto Kishi¹³⁷, Tomoo Ishii¹³⁸, Masayuki Kanai¹³⁹, Tomonori Imamura¹³⁹, Tatsuya Yamashita¹³⁹, Masakiyo Yatomi¹⁴⁰, Toshitaka Maeno¹⁴⁰, Shinichi Hayashi¹⁴¹, Mai Takahashi¹⁴¹, Mizuki Kuramochi¹⁴¹, Isamu Kamimaki¹⁴¹, Yoshiteru Tominaga¹⁴¹, Mitsuyoshi Utsugi¹⁴², Akihiro Ono¹⁴², Toru Tanaka¹⁴³, Takeru Kashiwada¹⁴³, Kazue Fujita¹⁴³, Yoshinobu Saito¹⁴³, Masahiro Seike¹⁴³, Masahiro Kanai¹⁴⁴, Ryunosuke Saiki¹⁴⁵, Takayoshi Hyugaji¹⁴⁶, Eigo Shimizu¹⁴⁶, Kotoe Katayama¹⁴⁶, Satoru Miyawaki¹⁴⁷, Meiko Takahashi¹⁴⁸, Fumi-hiko Matsuda¹⁴⁸, Yosuke Omae¹⁴⁹, Yasuhito Nannya¹⁴⁵, Takafumi Ueno¹⁵⁰, Yukinori Okada^{46,47,55,151}, Ryuji Koike¹⁵², Yuko Kitagawa¹⁵³, Katsushi Tokunaga¹⁴⁹, Akinori Kimura¹⁵⁴, Seiya Imoto¹⁴⁶, Satoru Miyano²³, Seishi Ogawa^{145,155,156}, Takanori Kanai¹³, Koichi Fukunaga¹
- 1 Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
 - 2 Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan.
 - 3 Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan.
 - 4 Department of General Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan.
 - 5 Department of Emergency and Disaster Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan.
 - 6 Department of Cardiovascular Biology and Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan.
 - 7 Department of Internal Medicine and Rheumatology, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan.
 - 8 Department of Nephrology, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan.
 - 9 Atopy (Allergy) Research Center, Juntendo University Graduate School of Medicine, Tokyo, Japan.
 - 10 Department of Emergency and Critical Care Medicine, Keio University School of Medicine, Tokyo, Japan
 - 11 Department of Anesthesiology, Keio University School of Medicine, Tokyo, Japan.
 - 12 Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan
 - 13 Division of Gastroenterology and Hepatology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
 - 14 Keio University Health Center
 - 15 Department of Organoid Medicine, Keio University School of Medicine, Tokyo, Japan.
 - 16 Department of Respiratory Medicine, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan.
 - 17 Department of Infection Control, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan.
 - 18 JCHO (Japan Community Health Care Organization) Saitama Medical Center, Internal Medicine, Saitama, Japan.
 - 19 Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Kumagaya, Japan.
 - 20 Department of Respiratory Medicine, Tokyo Women's Medical University, Tokyo, Japan.
 - 21 Department of General Medicine, Tokyo Women's Medical University, Tokyo, Japan.
 - 22 Department of Emergency and Critical Care Medicine, Kansai Medical University General Medical Center, Moriguchi, Japan.
 - 23 M&D Data Science Center, Tokyo Medical and Dental University, Tokyo, Japan.
 - 24 Clinical Research Center, Tokyo Medical and Dental University Hospital of Medicine, Tokyo, Japan.
 - 25 Department of Medical Informatics, Tokyo Medical and Dental University Hospital of Medicine, Tokyo, Japan.
 - 26 Respiratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
 - 27 Clinical Laboratory, Tokyo Medical and Dental University Hospital of Medicine, Tokyo, Japan.
 - 28 Department of Insured Medical Care Management, Tokyo Medical and Dental University Hospital of Medicine, Tokyo, Japan
 - 29 Fukujuji Hospital, Kiyose, Japan.
 - 30 Kawasaki Municipal Ida Hospital, Department of Internal Medicine, Kawasaki, Japan.
 - 31 Department of Infectious Diseases, Tosei General Hospital, Seto, Japan.
 - 32 Department of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Japan.
 - 33 Department of Respiratory Medicine, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
 - 34 School of Veterinary Medicine, Kitasato University, Towada, Japan.
 - 35 Laboratory of Viral Infection I, Department of Infection Control and Immunology, Ōmura Satoshi Memorial Institute & Graduate School of Infection Control Sciences, Kitasato University, Tokyo, Japan.
 - 36 Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan
 - 37 Department of Infectious Diseases, Tohoku University Graduate School of Medicine, Sendai, Japan
 - 38 Saiseikai Utsunomiya Hospital, Utsunomiya, Japan.

- 39 Department of Pulmonary Medicine, Saitama City Hospital, Saitama, Japan.
- 40 Department of Infectious Diseases, Saitama City Hospital, Saitama, Japan.
- 41 Department of General Thoracic Surgery, Saitama City Hospital, Saitama, Japan.
- 42 Department of Pulmonary Medicine, Eiju General Hospital, Tokyo, Japan.
- 43 Division of Infection Control, Eiju General Hospital, Tokyo, Japan.
- 44 Department of Hematology, Eiju General Hospital, Tokyo, Japan.
- 45 Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Suita, Japan.
- 46 Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan.
- 47 Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita, Japan.
- 48 Department of Otorhinolaryngology-Head and Neck Surgery, Osaka University Graduate School of Medicine, Suita, Japan.
- 49 Department of Neurosurgery, Osaka University Graduate School of Medicine, Suita, Japan.
- 50 Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
- 51 Division of Infection Control and Prevention, Osaka University Hospital, Suita, Japan.
- 52 Department of Biomedical Ethics and Public Policy, Osaka University Graduate School of Medicine, Suita, Japan.
- 53 Department of Otolaryngology and Head and Neck Surgery, Kansai Rosai Hospital, Hyogo, Japan.
- 54 Department of Immunopathology, Immunology Frontier Research Center (WPI-IFReC), Osaka University, Suita, Japan.
- 55 The Center for Infectious Disease Education and Research (CiDER), Osaka University, Suita, Japan.
- 56 Department of Respiratory Medicine, Saiseikai Yokohamashi Nanbu Hospital, Yokohama, Japan.
- 57 Department of Clinical Laboratory, Saiseikai Yokohamashi Nanbu Hospital, Yokohama, Japan.
- 58 Internal Medicine, Internal Medicine Center, Showa University Koto Toyosu Hospital, Tokyo, Japan.
- 59 Internal Medicine, Sano Kosei General Hospital, Sano, Japan.
- 60 Ishikawa Prefectural Central Hospital, Kanazawa, Japan.
- 61 Tachikawa Hospital, Tachikawa, Japan.
- 62 Department of Emergency and Critical Care Medicine, Tokyo Women's Medical University Medical Center East, Tokyo, Japan.
- 63 Department of Medicine, Tokyo Women's Medical University Medical Center East, Tokyo, Japan.
- 64 Department of Pediatrics, Tokyo Women's Medical University Medical Center East, Tokyo, Japan.
- 65 Japan Community Health care Organization Kanazawa Hospital, Kanazawa, Japan.
- 66 Department of Respiratory Medicine, Japan Organization of Occupational Health and Safety, Kanto Rosai Hospital, Kawasaki, Japan.
- 67 Department of General Internal Medicine, Japan Organization of Occupational Health and Safety, Kanto Rosai Hospital, Kawasaki, Japan.
- 68 Sapporo City General Hospital, Sapporo, Japan.
- 69 Department of Emergency and Critical Care Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
- 70 Department of Infection Control, Fukuoka University Hospital, Fukuoka, Japan.
- 71 Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan.
- 72 Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
- 73 Department of Allergy, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
- 74 Department of General Internal Medicine and Infectious Diseases, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
- 75 Department of Respiratory Medicine, Toyohashi Municipal Hospital, Toyohashi, Japan.
- 76 Keiyu Hospital, Yokohama, Japan.
- 77 Division of Respiratory Medicine, Social Welfare Organization Saiseikai Imperial Gift Foundation, Inc., Saiseikai Kumamoto Hospital, Kumamoto, Japan.
- 78 KKR Sapporo Medical Center, Department of respiratory medicine, Sapporo, Japan.
- 79 Division of General Internal Medicine, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
- 80 Department of Emergency and Critical Care Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
- 81 Japanese Red Cross Medical Center, Tokyo, Japan.
- 82 Matsumoto City Hospital, Matsumoto, Japan.
- 83 Department of Rheumatology, National Hospital Organization Hokkaido Medical Center, Sapporo, Japan.
- 84 Department of Respiratory Medicine, National Hospital Organization Hokkaido Medical Center, Sapporo, Japan.
- 85 Department of Emergency and Critical Care Medicine, National Hospital Organization Hokkaido Medical Center, Sapporo, Japan.
- 86 NHO Kanazawa Medical Center, Kanazawa, Japan.
- 87 Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine, Chiba, Japan.
- 88 Department of Emergency and Critical Care Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.
- 89 Nihon University School of Medicine, Department of Internal Medicine, Division of Respiratory Medicine, Tokyo, Japan.
- 90 Musashino Red Cross Hospital, Musashino, Japan.
- 91 Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- 92 Ome Municipal General Hospital, Ome, Japan.
- 93 Fukuoka Tokushukai Hospital, Department of Internal Medicine, Kasuga, Japan.
- 94 Fukuoka Tokushukai Hospital, Respiratory Medicine, Kasuga, Japan.
- 95 National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.
- 96 Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Tokorozawa, Japan.
- 97 Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan.
- 98 Department of Respiratory Medicine, Fujisawa City Hospital, Fujisawa, Japan.
- 99 Department of Internal Medicine, Tokyo Saiseikai Central Hospital, Tokyo, Japan.
- 100 Department of Pulmonary Medicine, Tokyo Saiseikai Central Hospital, Tokyo, Japan.
- 101 Uji-Tokushukai Medical Center, Uji, Japan.
- 102 Department of Infectious Disease and Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
- 103 Department of Respiratory Medicine, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.

- 104 Division of Respiriology, Rheumatology, and Neurology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan.
- 105 Department of Infectious Disease, National Hospital Organization Kyushu Medical Center, Fukuoka Japan.
- 106 Department of Cardiology, Pulmonology, and Nephrology, Yamagata University Faculty of Medicine, Yamagata, Japan.
- 107 Department of Pulmonary Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
- 108 Department of Emergency and Critical Care Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
- 109 Department of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
- 110 Department of Nephrology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
- 111 Department of Cardiovascular Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
- 112 Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- 113 Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
- 114 Daini Osaka Police Hospital, Osaka, Japan.
- 115 Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Isehara, Japan.
- 116 Department of Anesthesiology and Intensive Care Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
- 117 Department of Infection Control and Laboratory Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
- 118 Department of Respiratory Internal Medicine, St. Marianna University School of Medicine, Yokohama-City Seibu Hospital, Yokohama, Japan.
- 119 Gifu University School of Medicine Graduate School of Medicine, Emergency and Disaster Medicine, Gifu, Japan.
- 120 KINSHUKAI Hanwa The Second Hospital, Osaka, Japan.
- 121 Department of Respiratory Medicine, Tokyo Medical University Hospital, Tokyo, Japan.
- 122 JA Toride medical hospital, Toride, Japan.
- 123 Okayama Rosai Hospital, Okayama, Japan.
- 124 Himeji St. Mary's Hospital, Himeji, Japan.
- 125 Emergency & Critical Care, Niigata University, Niigata, Japan.
- 126 Emergency & Critical Care Center, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
- 127 National Hospital Organization Tokyo National Hospital, Kiyose, Japan.
- 128 Fujioka General Hospital, Fujioka, Japan.
- 129 Department of General Medicine, School of Medicine, International University of Health and Welfare Shioya Hospital, Ohtawara Japan.
- 130 Department of Pharmacology, School of Pharmacy, International University of Health and Welfare Shioya Hospital, Ohtawara Japan.
- 131 Department of Respiratory Medicine, International University of Health and Welfare Shioya Hospital, Ohtawara Japan.
- 132 Department of Clinical Laboratory, International University of Health and Welfare Shioya Hospital, Ohtawara Japan.
- 133 Department of General Medicine, School of Medicine, International University of Health and Welfare, Narita Japan.
- 134 Health and Welfare, Narita Japan.
- 135 Department of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan.
- 136 Kansai Electric Power Hospital, Osaka, Japan.
- 137 Department of Infectious Diseases, Kumamoto City Hospital, Kumamoto, Japan.
- 138 Department of Respiratory Medicine, Kumamoto City Hospital, Kumamoto, Japan.
- 139 Tokyo Medical University Ibaraki Medical Center, Inashiki, Japan.
- 140 Department of Emergency and Critical Care Medicine, Tokyo Metropolitan Police Hospital, Tokyo, Japan.
- 141 Department of Respiratory Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan.
- 142 National hospital organization Saitama Hospital, Wako, Japan.
- 143 Department of Internal Medicine, Kiryu Kosei General Hospital, Kiryu, Japan.
- 144 Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan
- 145 Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.
- 146 Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.
- 147 Division of Health Medical Intelligence, Human Genome Center, the Institute of Medical Science, the University of Tokyo, Tokyo, Japan.
- 148 Department of Neurosurgery, Faculty of Medicine, the University of Tokyo, Tokyo, Japan.
- 149 Center for Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- 150 Genome Medical Science Project (Toyama), National Center for Global Health and Medicine, Tokyo, Japan.
- 151 Department of Biomolecular Engineering, Graduate School of Tokyo Institute of Technology, Tokyo, Japan.
- 152 Laboratory of Statistical Immunology, Immunology Frontier Research Center (WPI-IFReC), Osaka University, Suita, Japan.
- 153 Medical Innovation Promotion Center, Tokyo Medical and Dental University, Tokyo, Japan.
- 154 Department of Surgery, Keio University School of Medicine, Tokyo, Japan.
- 155 Institute of Research, Tokyo Medical and Dental University, Tokyo, Japan.
- 156 Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan.
- 157 Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgement

We would like to thank all the participants involved in this study, and all the members of Japan COVID-19 Task Force engaging in clinical and research work on COVID-19 every day. All these members contributed to the accumulation of cases in this study.

References

- Chen N, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020;395(10223):507–13. doi:[10.1016/S0140-6736\(20\)30211-7](https://doi.org/10.1016/S0140-6736(20)30211-7).
- Guan WJ, et al. Clinical characteristics of Coronavirus disease 2019 in China. *N Engl J Med* 2020;382(18):1708–20. doi:[10.1056/NEJMoa2002032](https://doi.org/10.1056/NEJMoa2002032).
- Horby P, et al. Dexamethasone in hospitalized patients with Covid-19. *N Engl J Med* 2021;384(8):693–704. doi:[10.1056/NEJMoa2021436](https://doi.org/10.1056/NEJMoa2021436).
- Macedo A, et al. COVID-19 fatality rates in hospitalized patients: systematic review and meta-analysis. *Ann Epidemiol* 2021;57:14–21. doi:[10.1016/j.annepidem.2021.02.012](https://doi.org/10.1016/j.annepidem.2021.02.012).
- Matsunaga N, et al. Clinical epidemiology of hospitalized patients with COVID-19 in Japan: Report of the COVID-19 REGISTRY JAPAN. *Clin Infect Dis* 2020 ciaa1470 (Online ahead of print). doi:[10.1093/cid/ciaa1470](https://doi.org/10.1093/cid/ciaa1470).
- Ministry of Health, Labour and Welfare. 2021 "Situation Report." from <https://www.mhlw.go.jp/stf/covid-19/kokunainohasseijoukyou.html>. [Accessed June 2021].

- Namkoong H, et al. "Japan COVID-19 Task Force: a nation-wide consortium to elucidate host genetics of COVID-19 pandemic in Japan." medRxiv 2021. 10.1101/2021.05.17.21256513
- World Health Organization. "Novel Coronavirus: COVID-19 Therapeutic Trial Synopsis." (February 18, 2020) from https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf.
- Price-Haywood EG, et al. Hospitalization and mortality among Black patients and White patients with Covid-19. N Engl J Med 2020;382(26):2534–43. doi:[10.1056/NEJMsa2011686](https://doi.org/10.1056/NEJMsa2011686).
- Zeberg H, Pääbo S. The major genetic risk factor for severe COVID-19 is inherited from Neanderthals. Nature 2020;587(7835):610–12. doi:[10.1038/s41586-020-2818-3](https://doi.org/10.1038/s41586-020-2818-3).